Wyeth, Progenics drug flunks trial

Wyeth and Progenics were handed a serious blow today when their intravenous drug methylnaltrexone for postoperative ileus flunked the first of two Phase III trials. Initial results from the study showed that the drug didn't reduce time to recovery of gastrointestinal function more effectively than placebo. In addition, methylnaltrexone wasn't superior to placebo for surgical recovery. In a statement, Progenics founder and CEO Paul Maddon said the results were inconsistent with earlier trials.

"Despite the results of this Phase III trial for POI, we remain confident in the methylnaltrexone development program," says Robert Ruffolo, Ph.D., President, Research and Development, Wyeth Pharmaceuticals. "We will continue to develop the methylnaltrexone franchise to help address the unmet medical need of patients suffering with the gastrointestinal side effects of opioids." Investors crushed Progenics stock on the news, sending shares down over 50 percent to $6.

- see this press release for more

ALSO: It's been a bad day all around for Wyeth. The company has pulled its European application for desvenlafaxine. Release

Related Articles:
FDA wants time to ponder Progenics, Wyeth drug. Report
Wyeth, Progenics drug gets fast-tracked. Report
Progenics launches Phase II trial. Report
Wyeth stumbles badly trying to develop new drugs. Report

Suggested Articles

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.